BioLogic Equity Research is an independent research firm serving the institutional investor community. We are dedicated to providing our clients with the highest quality unbiased and in-depth research focused exclusively on the development of biotechnology and specialty pharmaceutical products and emerging medical technologies.

BER's professionals have extensive sell-side and buy-side research experience as well as a developed network of industry experts across numerous therapeutic areas. Though concentrated primarily on early and mid-stage biotechnology and medical technology companies, our coverage universe spans the entire therapeutics space, including pharmaceuticals and medical devices.

BER’s stock selection criteria is skewed toward high-alpha binary events such as FDA regulatory action dates, clinical data releases and potentially disruptive products either entering markets or in late-stage development.